Viewing Study NCT02189720

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:13 AM
Ignite Modification Date: 2026-02-24 @ 8:50 AM
Study NCT ID: NCT02189720
Status: APPROVED_FOR_MARKETING
Last Update Posted: 2025-03-26
First Post: 2014-07-05
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome
Sponsor: Catalyst Pharmaceuticals, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Congenital Myasthenic Syndrome View
None Lambert-Eaton Myasthenic Syndrome View
None Nystagmus, Acquired View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Amifampridine Phosphate View
None Amifampridine View
None 3,4-Diaminopyridine Phosphate View
None 3,4-Diaminopyridine View
None 3,4-DAP View
None CMS View
None Congenital Myasthenic Syndrome View
None Neuromuscular View
None Expanded Access View
None Firdapse® View
None LEMS View